



Metastatic Breast Cancer Research Conference

Clinical | Basic Science | Survivorship

September 12-13, 2014

University of Kansas Medical Center – Beller Conference Center

THE UNIVERSITY
OF KANSAS
CANCER CENTER



Agenda

Friday, September 12, 2014

2:30 p.m.	Registration and Exhibits
3:00 p.m.	Introductory Remarks <i>Dan Welch & Josh Newby</i>
3:05 p.m.	Advances in the Management of Triple Negative Breast Cancer <i>Cynthia Ma, MD, PhD</i>
3:40 p.m.	BRCA1 & Mechanistic Studies of EGFR Expression in Breast Cancer <i>Roy Jensen, MD</i>
4:15 p.m.	Prolyl isomerase inhibitors as breast cancer metastasis inhibitors <i>Charles Clevenger, MD, PhD</i>
5:00 p.m.	Investigating the inherited susceptibility to breast cancer metastasis <i>Kent Hunter, PhD</i>
6:00 p.m.	Dinner <i>Catered by Oklahoma Joe's</i>

Saturday, September 13, 2014

7:30 a.m.	Registration, Exhibits and Breakfast (<i>catered by Grandma's Office Catering</i>)
8:00 a.m.	Announcements
8:05 a.m.	Emerging connections between cancer metastasis and metabolism <i>Dan Welch, PhD</i>
8:35 a.m.	Advances in breast cancer immune therapy <i>William Gillanders, MD</i>
9:05 a.m.	HER2- negative cancers may benefit from anti-HER2 therapy <i>Ron Bose, MD, PhD</i>
9:35 a.m.	Break
10:05 a.m.	Exploiting BRCAness for treatment of triple negative breast cancer: Hope or hype <i>Priyanka Sharma, MD</i>
10:35 a.m.	Preventing Cardiac Dysfunction in Breast Cancer Survivors <i>Carol Fabian, MD</i>
11:05 a.m.	Integrating Palliative Care into the active treatment phase: how we do it and why <i>Karin Porter-Williamson, MD</i>
11:35 a.m.	Survivorship Issues in the Metastatic Setting <i>Jennifer Klemp, PhD, MPH</i>
12:05 p.m.	Discussion & closing remarks
12:30 p.m.	Lunch (<i>Catered by Schlotzsky's</i>)

Course Director

Danny R Welch, PhD, Professor and Chair of Cancer Biology; Associate Director for Basic Sciences, University of Kansas Medical Center, Kansas City, KS.

Course Co-director

Jennifer R. Klemp, PhD, MPH, Associate Professor of Medicine; Managing Director, Breast Cancer Survivorship Center, University of Kansas Medical Center, Kansas City, KS.

Faculty

Ron Bose, MD, PhD, Assistant Professor of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO.

Charles Clevenger, MD, PhD, Professor and Chair, Department of Pathology, Virginia Commonwealth University, Richmond, VA.

Carol Fabian, MD, Distinguished Professor of Hematology/Oncology, University of Kansas Medical Center; Director, Breast Cancer Prevention and Survivorship Centers; Morris Family Endowed Chair in Cancer Prevention, Westwood, KS.

William Gillanders, MD, Professor of Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO.

Kent Hunter, PhD, Head, Metastasis Susceptibility Section; Sr. Investigator, Center for Cancer Research, National Cancer Institute, Bethesda, MD.

Roy Jensen, MD, Director, The University of Kansas Cancer Center and Professor of Pathology, University of Kansas Medical Center, Kansas City, KS.

Jennifer R. Klemp, PhD, MPH, Associate Professor of Medicine; Managing Director, Breast Cancer Survivorship Center, University of Kansas Medical Center, Kansas City, KS.

Cynthia Ma, MD, PhD, Associate Professor of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO.

Karin Porter-Williamson, MD, Associate Professor of Internal Medicine, University of Kansas Medical Center, Kansas City, KS.

Priyanka Sharma, MD, Associate Professor of Hematology/Oncology, University of Kansas Medical Center, Kansas City, KS.

Danny R. Welch, PhD, Professor and Chair of Cancer Biology; Associate Director for Basic Sciences, University of Kansas Medical Center, Kansas City, KS.

Overview

Metastatic, stage IV, or advanced breast cancers are defined by spread beyond the breast into other body systems. Metastases account for greater than 90% of cancer morbidity and mortality. This translates into nearly 40,000 deaths each year in the U.S. and ~500,000 worldwide. Metastatic breast cancer is the leading cause of cancer death in women below 50 years of age.

This Conference presents updates on Basic Science, Clinical, and Survivorship issues that relate to the development, treatment and sequelae of metastatic breast cancer. The integration of all three aspects is presented with the belief that all three phases are needed to understand and effectively treat metastatic breast cancer. The conference will also focus on collaborations.

Target Audience

This symposium is designed for physicians, nurses, healthcare professionals, researchers and others who participate in the care of patients with breast cancer, especially metastatic cancer.

Objectives

At the completion of this symposium participants should be able to:

- Explain how BRCA1 mediates tumor suppression via a variety of mechanisms including control of EGFR expression
- Discuss the differences between mitochondrial inheritance and nuclear inheritance
- Apply knowledge of palliative care needs to practice in a timely manner
- Increase integration of Palliative services into outpatient settings, as measured by existence or growth of program/referral base
- Explain of the role of inherited predisposition for metastatic disease

Accreditation

All participants are required to sign attendance rosters at the beginning of each day. A certificate of completion will be provided to all activity participants based on completion of the program evaluation, documentation of actual attendance time, meeting minimum attendance requirements specific to the activity, **and payment in full. If you are not paid in full, a link to complete evaluation and get your certificate will be emailed to you upon receipt of payment.**

Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint provider ship of the University of Kansas Medical Center Office of Continuing Medical Education and Theresa's Foundation. The University of Kansas Medical Center Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The KU Medical Center Office of Continuing Medical Education designates this live activity for a maximum of 7.0 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: The University of Kansas Medical Center Area Health Education Center East, as an approved provider of continuing education by the Kansas State Board of Nursing, presents this offering for a maximum of 7.0 contact hour's credit applicable for relicensure of APRNs, RNs and LPNs. Kansas Provider Number LT0056-0749

Continuing education credit will be prorated according to documented attendance.

New Online Procedure for CE Certificate and Program Evaluation:

- All participants will be emailed a link to complete the evaluation.
- **Physicians** will be able to print a certificate upon completion of the evaluation.
- **Nurses** will receive a certificate in the mail.
- You should receive the email from Suzy Williams, Program Coordinator **within three days after the completion of the course.**
- If you do not receive this in your inbox, check your spam/junk mailbox. You may also contact Suzy at swilliams16@kumc.edu or 913-588-4488 if you did not receive it, and she will send you another email.



Acknowledgements

Contributors:

The following organization has generously supported this conference and we acknowledge them with sincerest appreciation.

Eisai

Exhibitors:

We wish to acknowledge and sincerely thank these organizations
for exhibiting at this conference.

Amgen

Celgene

Eisai

Genentech

NanoString

Faculty and Planning Committee Disclosure Information

Disclosure of Relevant Financial Arrangements

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC), the University of Kansas Medical Center Continuing Education & Professional Development must ensure that the health and well-being of the public is more important than any economic interest, and that activity content is effective in improving practice, independent of commercial interests, and based on valid content. Individuals with control over the content of this activity are required to disclose to the learners any relevant financial relationships within the past 12 months with any proprietary entities producing, marketing, re-selling, or distributing healthcare goods or services related to the content of the activity (with the exemption of non-profit or governmental organizations and non-healthcare related companies). This includes any relevant financial arrangements involving their spouse/partner. Relevant financial relationships may include employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, etc. The intent of this disclosure is not to prevent an individual with a relevant financial relationship from being a planning committee member, a teacher, or an author of CME/CNE having control of, or responsibility for, the development, management, presentation, or evaluation of the CME/CNE activity, but rather to assist the provider in the identification and resolution of conflict of interest prior to the activity and to provide the learners with the information they need to determine whether these interests or relationships influenced the content of the activity.

The following presenters have disclosed relevant financial relationships with proprietary entities producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on patients related to the content of their presentations:

Priyanka Sharma, MD – has received grants from Myriad Genetic Laboratories, Roche (Genentech) and GSK for her participation in performance improvement studies.

Cynthia Ma, MD – has received honorariums from Novartis, Pfizer and Puma for her role as a researcher.

Ron Bose, MD – has received an honorarium from Novartis for his role as a speaker.

The following presenters do not have any relevant financial relationships with any proprietary entities producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on patients related to the content of their presentations:

Charles Clevenger, MD, PhD
Kent Hunter, MD

Roy Jensen, MD
Karin Porter-Williamson, MD

William Gillanders, MD
Carol Fabian, MD

The following planning committee members do not have any relevant financial relationships with any proprietary entities producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on patients related to the content of the activity:

Lori Ranallo, RN
Pam Simpson, MBA, CMP

Josh Newby

Matthew Ellis, MD

The following presenter/planning committee member does not have any relevant financial relationships with any proprietary entities producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on patients related to the content of their presentations or related to the content of the activity:

Danny Welch, PhD

Jennifer Klemp, PhD

Resolution of Conflict of Interest

A conflict of interest, or a potential for bias, exists if an individual/entity in a position to benefit financially from the success of a continuing education activity is also in a position to influence its content, design, or implementation. For this continuing education activity, conflict of interest was resolved and successful resolution of conflict of interest will be validated through the implementation of the following mechanisms.

- Relevant financial relationships were disclosed and resolved prior to everyone's participation in the planning, development, and implementation of this activity.
- Prior to participating in this activity, everyone in a position to influence its content, design or implementation received our terms and conditions regarding conflict of interest expectations and they agreed to comply.
- Speakers were selected based upon a review of their qualifications and an assessment of their ability to present the best available evidence accepted in health care practice.
- Clinical content was validated by a review of the activity for fair balance and bias, appropriate patient treatment recommendations, and whether scientific studies cited in the activity conform to standards accepted by the scientific community.
- Oversight will be maintained by monitoring the planning, development, and implementation of this continuing education activity.
- Disclosure of relevant financial relationships will be provided to the participants prior to the activity.
- Participants will evaluate the activity's success in resolving conflict of interest and providing an activity free of bias.

Product Disclosures

Unless otherwise announced prior to the session, this activity does not include any information about off-label use of a product for a purpose other than that for which it was approved by the Food and Drug Administration (FDA).

Noncommercial Sponsor Support

There is no noncommercial sponsor support for this CE activity.